Insights Into Lung Cancer

Perspectives on management of patients with NSCLC and EGFR or ALK mutations, current use of treatment options including immunotherapy in advanced NSCLC, and treatment of progressive disease

Meeting Moderator

Sushil Bhardwaj, MD

Good Samaritan Hospital Suffern, NY, USA

Look Inside This Report

Download a sample of this report and start discovering the insights

Report Snapshot

Insights on the following therapies were obtained

  • afatinib
  • alectinib
  • atezolizumab
  • bevacizumab
  • brigatinib
  • carboplatin
  • ceritinib
  • crizotinib
  • dacomitinib
  • docetaxel
  • erlotinib
  • gefitinib
  • gemcitabine
  • lorlatinib
  • nab-paclitaxel
  • necitumumab
  • nivolumab
  • osimertinib
  • pembrolizumab
  • pemetrexed
  • ramucirumab


  • A moderated roundtable discussion focusing on treatment of NSCLC was held on August 24, 2019, in Washington, DC, USA
  • Disease state and data presentations were developed in conjunction with a medical expert from Indiana University
  • The group of advisors comprised 12 community oncologists
  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion

Explore Available and Upcoming Insight Reports

View Reports